iBio, Inc. Common Stock (IBIO) - Total Assets
Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) holds total assets worth $99.11 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
iBio, Inc. Common Stock - Total Assets Trend (2007–2026)
This chart illustrates how iBio, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see iBio, Inc. Common Stock (IBIO) total market value for the company's overall valuation and market capitalisation.
iBio, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (June 2026)
iBio, Inc. Common Stock's total assets of $99.11 Million consist of 93.1% current assets and 7.0% non-current assets. Review how much debt does iBio, Inc. Common Stock carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 56.9% |
| Accounts Receivable | $1.10 Million | 1.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.82 Million | 1.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2026)
This chart illustrates how iBio, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See IBIO stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: iBio, Inc. Common Stock's current assets represent 93.1% of total assets in 2026, an increase from 4.7% in 2007.
- Cash Position: Cash and equivalents constituted 56.9% of total assets in 2026, up from 0.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 88.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 1.8% of total assets.
iBio, Inc. Common Stock Competitors by Total Assets
Key competitors of iBio, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
iBio, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.85 | 1.59 | 11.09 |
| Quick Ratio | 7.85 | 1.59 | 11.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $80.48 Million | $3.62 Million | $81.72 Million |
iBio, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between iBio, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | 327.5% |
| Total Assets | $99.11 Million |
| Market Capitalization | $80.38 Million USD |
Valuation Analysis
Near Book Valuation: The market values iBio, Inc. Common Stock's assets close to their book value (0.81x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: iBio, Inc. Common Stock's assets grew by 327.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for iBio, Inc. Common Stock (2007–2026)
The table below shows the annual total assets of iBio, Inc. Common Stock from 2007 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $99.11 Million | +327.47% |
| 2025-06-30 | $23.18 Million | -19.31% |
| 2024-06-30 | $28.73 Million | -30.27% |
| 2023-06-30 | $41.21 Million | -58.55% |
| 2022-06-30 | $99.41 Million | -32.36% |
| 2021-06-30 | $146.97 Million | +56.04% |
| 2020-06-30 | $94.19 Million | +207.95% |
| 2019-06-30 | $30.59 Million | -29.01% |
| 2018-06-30 | $43.08 Million | +19.64% |
| 2017-06-30 | $36.01 Million | -30.21% |
| 2016-06-30 | $51.60 Million | +313.00% |
| 2015-06-30 | $12.49 Million | +92.39% |
| 2014-06-30 | $6.49 Million | -30.58% |
| 2013-06-30 | $9.35 Million | -4.20% |
| 2012-06-30 | $9.76 Million | +33.11% |
| 2011-06-30 | $7.34 Million | +48.79% |
| 2010-06-30 | $4.93 Million | 0.00% |
| 2009-06-30 | $4.93 Million | +38.91% |
| 2008-06-30 | $3.55 Million | -5.81% |
| 2007-06-30 | $3.77 Million | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more